October 27, 2025
Unlocking Japan’s Potential in Rare Disease Drug Development: Recent Progress and Challenges (2025)
rare disease; Japan; orphan drug; drug lag; innovation; regulatory approval; pharmaceutical partnerships; clinical trials
From JP Morgan to the Next Wave: What’s Driving Biotech in 2026
J.P. Morgan Healthcare Conference; biotech trends 2026; M&A activity; oncology; neuropsychology; hematology; artificial intelligence; drug discovery; investment; regulatory science
Novartis CEO on $12B Avidity Deal: ‘Could Have Been Twice as Big’
Novartis; Avidity Biosciences; Vas Narasimhan; merger; acquisition; biotech; RNA therapeutics; $12 billion deal; neuromuscular diseases; SpinCo; financial outlook; growth strategy
Bayer Receives FDA Approval for Lynkuet, a Novel Non-Hormonal Drug for Menopausal Hot Flashes
Bayer; FDA approval; Lynkuet; elinzanetant; hot flashes; menopause; non-hormonal; NK1/NK3 receptors; vasomotor symptoms
FDA Approves Syndax’s First-in-Class Menin Inhibitor with Black-Box Warning; Updates on GSK’s ADC Deal
Syndax; Revuforj; revumenib; FDA approval; menin inhibitor; black-box warning; acute leukemia; KMT2A translocation; differentiation syndrome; acute myeloid leukemia (AML); GSK; antibody-drug conjugate (ADC); oncology drug approval
Philadelphia on Lilly’s Radar for Next Gateway Labs Site
Lilly Gateway Labs; Philadelphia; Biotech Innovation
Halda’s HLD-0915 Shows Promising First-in-Human Results as a Safer RIPTAC Cancer Therapeutic
Halda Therapeutics; HLD-0915; RIPTAC; metastatic castration-resistant prostate cancer; first-in-human; safety; anti-tumor activity; oral therapeutic
FDA Approves Bayer’s Lynkuet for Menopausal Hot Flashes
FDA approval; Bayer; Lynkuet; menopause; hot flashes
Novartis to Acquire RNA Drugmaker Avidity Biosciences in $12 Billion Deal
Novartis; Avidity Biosciences; acquisition; RNA therapeutics; neuromuscular diseases; Duchenne muscular dystrophy; myotonic dystrophy type 1; facioscapulohumeral muscular dystrophy; AOC platform; SpinCo; biotech; xRNA strategy; 2026 closing
MapLight Therapeutics Announces Pricing of $17/share IPO; to Raise Over $250 Million, Begins Trading on Nasdaq
MapLight Therapeutics; IPO; Initial Public Offering; Nasdaq; MPLT; Schizophrenia; Alzheimer’s disease psychosis; CNS disorders; Phase 2 clinical trials; Biotech